Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis

M. Di Filippo, L. A. Pini, G. P. Pelliccioli, P. Calabresi, Paola Sarchielli

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: Endocannabinoids (eCBs) play a role in the modulation of neuroinflammation, and experimental findings suggest that they may be directly involved in the pathogenesis of multiple sclerosis (MS). The objective of our study was to measure eCB levels in the cerebrospinal fluid (CSF) of patients with MS. Patients and methods: Arachidonoylethanolamine (anandamide, AEA), palmotylethanolamide (PEA), 2-arachidonoylglycerol (2-AG) and oleoylethanolamide (OEA) levels were measured in the CSF of 50 patients with MS and 20 control subjects by isotope dilution gas-chromatography/mass-spectrometry. Patients included 35 patients with MS in the relapsing-remitting (RR) form of the disease, 20 in a stable clinical phase and 15 during a relapse, and 15 patients with MS in the secondary progressive (SP) form. Results: Significantly reduced levels of all the tested eCBs were found in the CSF of patients with MS compared to control subjects, with lower values detected in the SP MS group. Higher levels of AEA and PEA, although below those of controls, were found in the CSF of RR MS patients during a relapse. Higher levels of AEA, 2-AG and OEA were found in patients with MRI gadolinium-enhancing (Gd+) lesions. Discussion: The present findings suggest the presence of an impaired eCB system in MS. Increased CSF levels of AEA during relapses or in RR patients with Gd+ lesions suggest its potential role in limiting the ongoing inflammatory process with potential neuroprotective implications. These findings provide further support for the development of drugs targeting eCBs as a potential pharmacological strategy to reduce the symptoms and slow disease progression in MS.

Original languageEnglish
Pages (from-to)1224-1229
Number of pages6
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume79
Issue number11
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Endocannabinoids
Multiple Sclerosis
Cerebrospinal Fluid
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Recurrence
Gadolinium
Drug Delivery Systems
Isotopes
Gas Chromatography-Mass Spectrometry
Disease Progression
Pharmacology

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery

Cite this

Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. / Di Filippo, M.; Pini, L. A.; Pelliccioli, G. P.; Calabresi, P.; Sarchielli, Paola.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 79, No. 11, 11.2008, p. 1224-1229.

Research output: Contribution to journalArticle

Di Filippo, M. ; Pini, L. A. ; Pelliccioli, G. P. ; Calabresi, P. ; Sarchielli, Paola. / Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. In: Journal of Neurology, Neurosurgery and Psychiatry. 2008 ; Vol. 79, No. 11. pp. 1224-1229.
@article{8dd1cbe034644b43a0918911b7885657,
title = "Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis",
abstract = "Objective: Endocannabinoids (eCBs) play a role in the modulation of neuroinflammation, and experimental findings suggest that they may be directly involved in the pathogenesis of multiple sclerosis (MS). The objective of our study was to measure eCB levels in the cerebrospinal fluid (CSF) of patients with MS. Patients and methods: Arachidonoylethanolamine (anandamide, AEA), palmotylethanolamide (PEA), 2-arachidonoylglycerol (2-AG) and oleoylethanolamide (OEA) levels were measured in the CSF of 50 patients with MS and 20 control subjects by isotope dilution gas-chromatography/mass-spectrometry. Patients included 35 patients with MS in the relapsing-remitting (RR) form of the disease, 20 in a stable clinical phase and 15 during a relapse, and 15 patients with MS in the secondary progressive (SP) form. Results: Significantly reduced levels of all the tested eCBs were found in the CSF of patients with MS compared to control subjects, with lower values detected in the SP MS group. Higher levels of AEA and PEA, although below those of controls, were found in the CSF of RR MS patients during a relapse. Higher levels of AEA, 2-AG and OEA were found in patients with MRI gadolinium-enhancing (Gd+) lesions. Discussion: The present findings suggest the presence of an impaired eCB system in MS. Increased CSF levels of AEA during relapses or in RR patients with Gd+ lesions suggest its potential role in limiting the ongoing inflammatory process with potential neuroprotective implications. These findings provide further support for the development of drugs targeting eCBs as a potential pharmacological strategy to reduce the symptoms and slow disease progression in MS.",
author = "{Di Filippo}, M. and Pini, {L. A.} and Pelliccioli, {G. P.} and P. Calabresi and Paola Sarchielli",
year = "2008",
month = "11",
doi = "10.1136/jnnp.2007.139071",
language = "English",
volume = "79",
pages = "1224--1229",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis

AU - Di Filippo, M.

AU - Pini, L. A.

AU - Pelliccioli, G. P.

AU - Calabresi, P.

AU - Sarchielli, Paola

PY - 2008/11

Y1 - 2008/11

N2 - Objective: Endocannabinoids (eCBs) play a role in the modulation of neuroinflammation, and experimental findings suggest that they may be directly involved in the pathogenesis of multiple sclerosis (MS). The objective of our study was to measure eCB levels in the cerebrospinal fluid (CSF) of patients with MS. Patients and methods: Arachidonoylethanolamine (anandamide, AEA), palmotylethanolamide (PEA), 2-arachidonoylglycerol (2-AG) and oleoylethanolamide (OEA) levels were measured in the CSF of 50 patients with MS and 20 control subjects by isotope dilution gas-chromatography/mass-spectrometry. Patients included 35 patients with MS in the relapsing-remitting (RR) form of the disease, 20 in a stable clinical phase and 15 during a relapse, and 15 patients with MS in the secondary progressive (SP) form. Results: Significantly reduced levels of all the tested eCBs were found in the CSF of patients with MS compared to control subjects, with lower values detected in the SP MS group. Higher levels of AEA and PEA, although below those of controls, were found in the CSF of RR MS patients during a relapse. Higher levels of AEA, 2-AG and OEA were found in patients with MRI gadolinium-enhancing (Gd+) lesions. Discussion: The present findings suggest the presence of an impaired eCB system in MS. Increased CSF levels of AEA during relapses or in RR patients with Gd+ lesions suggest its potential role in limiting the ongoing inflammatory process with potential neuroprotective implications. These findings provide further support for the development of drugs targeting eCBs as a potential pharmacological strategy to reduce the symptoms and slow disease progression in MS.

AB - Objective: Endocannabinoids (eCBs) play a role in the modulation of neuroinflammation, and experimental findings suggest that they may be directly involved in the pathogenesis of multiple sclerosis (MS). The objective of our study was to measure eCB levels in the cerebrospinal fluid (CSF) of patients with MS. Patients and methods: Arachidonoylethanolamine (anandamide, AEA), palmotylethanolamide (PEA), 2-arachidonoylglycerol (2-AG) and oleoylethanolamide (OEA) levels were measured in the CSF of 50 patients with MS and 20 control subjects by isotope dilution gas-chromatography/mass-spectrometry. Patients included 35 patients with MS in the relapsing-remitting (RR) form of the disease, 20 in a stable clinical phase and 15 during a relapse, and 15 patients with MS in the secondary progressive (SP) form. Results: Significantly reduced levels of all the tested eCBs were found in the CSF of patients with MS compared to control subjects, with lower values detected in the SP MS group. Higher levels of AEA and PEA, although below those of controls, were found in the CSF of RR MS patients during a relapse. Higher levels of AEA, 2-AG and OEA were found in patients with MRI gadolinium-enhancing (Gd+) lesions. Discussion: The present findings suggest the presence of an impaired eCB system in MS. Increased CSF levels of AEA during relapses or in RR patients with Gd+ lesions suggest its potential role in limiting the ongoing inflammatory process with potential neuroprotective implications. These findings provide further support for the development of drugs targeting eCBs as a potential pharmacological strategy to reduce the symptoms and slow disease progression in MS.

UR - http://www.scopus.com/inward/record.url?scp=52949146989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949146989&partnerID=8YFLogxK

U2 - 10.1136/jnnp.2007.139071

DO - 10.1136/jnnp.2007.139071

M3 - Article

VL - 79

SP - 1224

EP - 1229

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 11

ER -